2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-159696
    ISIS 449884 1428588-67-3 98%
    ISIS 449884 is a 2'-O-methoxyethyl antisense oligonucleotide that targets GCGR. ISIS 449884 has an ability to reduce hepatic glucose output and lower the blood glucose level. ISIS 449884 can be used for the study of type 2 diabetes mellitus (T2DM).
    ISIS 449884
  • HY-159845
    Lecufexor 2247972-61-6 99.27%
    Lecufexor is a farnesoid X receptor (FXR) agonist.
    Lecufexor
  • HY-159881
    SHS206 98%
    SHS206 (compound 6n) is an orally active mitochondrial uncoupler that reduces hepatic triglyceride levels. SHS206 exhibits in vivo efficacy in the GAN mouse model and shows inhibitory effects on metabolic dysfunction-associated steatohepatitis (MASH).
    SHS206
  • HY-159962
    TGase2-IN-1 2244702-64-3 98%
    TGase2-IN-1 (Compound 22) is an orally active inhibitor for TGase2 with an IC50 of 1.12 μM. TGase2-IN-1 inhibits TGase2 in human retinal microvascular endothelial cells with an IC50 of 0.07 μM. TGase2-IN-1 exhibits 74.6% oral bioavailability. TGase2-IN-1 inhibits retinal vascular leakage in mouse Streptozotocin (HY-13753)-induced diabetic model.
    TGase2-IN-1
  • HY-160036
    PCSK9-IN-22 2794203-47-5 98%
    PCSK9-IN-22 (compound 29) is an orally active inhibitor of PCSK9. PCSK9-IN-22 inhibits the interaction of the protein with LDLR in vivo.
    PCSK9-IN-22
  • HY-160156
    SSTR5 antagonist 4 916338-03-9
    SSTR5 antagonist 4 (compound 1) is a potent, selective and orally active somatostatin subtype 5 (SSTR5) antagonist (hSSTR5 IC50 = 1.3 nM, mSSTR5 IC50 = 1.0 nM). SSTR5 antagonist 4 shows efficacy in mouse oral glucose tolerance test (OGTT) in high fat diet (HFD)-mice. SSTR5 antagonist 4 can be used for type 2 diabetes research.
    SSTR5 antagonist 4
  • HY-160159
    PPARγ modulator-1 1415321-54-8 98%
    Anticancer agent 183 (example 48) is a non-agonistic PPARG modulator. Anticancer agent 183 has a high affinity to PPARG (PPARγ). Anticancer agent 183 inhibits kinase-mediated phosphorylation of PPARG. Anticancer agent 183 can used for research on metabolic diseases to avoid side effects.
    PPARγ modulator-1
  • HY-160168
    BTK-IN-31 98%
    BTK-IN-31 (Compound 2) is a selective, non-covalently reversible, and blood-brain barrier (BBB) permeable Btk inhibitor. BTK-IN-31 has research potential in immune disorders, cancer, cardiovascular disease, viral infections, inflammation, metabolic/endocrine dysfunction, and neurological disorders.
    BTK-IN-31
  • HY-160176
    SSTR5 antagonist 6 1007836-12-5 98%
    SSTR5 antagonist 6 is an orally active somatostatin receptor subtype 5 (SSTR5) antagonist with an IC50 of 24 nM. SSTR5 antagonist 6 can be used in the study of type 2 diabetes.
    SSTR5 antagonist 6
  • HY-160208
    BI-8668 2084059-97-0 98%
    BI-8668 (compound 40), a chemical probe, is an inhibitor of ENaC. BI-8668 can be used in the study of cystic fibrosis.
    BI-8668
  • HY-160266
    THR-β agonist 7 2604229-32-3 98%
    THR-β agonist-1 (Example 2) is a THR-β agonist, with EC50 values of 52 nM and 1017 nM for THR-β and THR-α, respectively.
    THR-β agonist 7
  • HY-160461
    LTK-14A 71118-00-8
    LTK-14A, a derivative of Garcinol (HY-107569), is a selective histone butyrylation inhibitor. LTK-14A does not affect acetylation. LTK-14A significantly inhibits the butyrylation of H4K5 and downregulated the expression of proadipogenic genes, thus culminating in abolished adipogenesis. LTK-14A can be used for the study of obesity.
    LTK-14A
  • HY-160514
    LXQ46 2097148-94-0 99.14%
    LXQ46 is an orally active inhibitor for protein tyrosine phosphatase 1B (PTP1B), with an IC50 of 0.190 μM. LXQ46 enhances insulin and leptin signaling pathways in insulin-resistant C2C12. LXQ46 ameliorates type 2 diabetes and increases insulin tolerance in mouse models.
    LXQ46
  • HY-160547
    PROTAC AR Degrader-5 2703021-51-4 98%
    PROTAC AR Degrader-5 (compound A46) is a potent AR PROTACs degrader with an IC50 value of 49 nM. PROTAC AR Degrader-5 inhibits sebaceous plaque and induces hair regeneration.
    PROTAC AR Degrader-5
  • HY-160548
    mTOR inhibitor-18 2170358-67-3 98%
    mTOR inhibitor-18 (Example 106) is a mTOR inhibitor. mTOR inhibitor-18 can be used for mTOR related research, such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.
    mTOR inhibitor-18
  • HY-160628
    GPR120 Agonist 4 1628641-89-3 98%
    GPR120 Agonist 4 (example 1) is a GPR120 agonist，with the EC50 values of 1 μM and 0.35 μM for β-arrestin A and Calcium A. GPR120 Agonist 4 can be used for the research of type II diabetes mellitus.
    GPR120 Agonist 4
  • HY-160631
    GPR40 agonist 9 1877252-91-9
    GPR40 agonist 9 (Example 21) is a G protein-coupled receptor 40 (GPR40) agonist with an EC50 of 0.21 nM. GPR40 agonist 9 is applicable to research related to type 2 diabetes, obesity, and other associated conditions.
    GPR40 agonist 9
  • HY-160637
    Lp-PLA2-IN-17 1818842-74-8 98%
    Lp-PLA2-IN-17 (Compound 39) is an inhibitor of Lp-PLA2. Lp-PLA2-IN-17 can be used to study disorders involving the hydrolysis of oxidized lipids into two inflammatory substances with the participation of Lp-PLA2.
    Lp-PLA2-IN-17
  • HY-160676
    sEH-IN-1 1061377-99-8 98%
    sEH-IN-1 (example 67) is a soluble epoxide hydrolase (sEH) inhibitor. sEH-IN-1 can be used in the research of sEH-mediated diseases such as hypertension, cardiovascular disease, inflammation, diabetes, and so on.
    sEH-IN-1
  • HY-161005
    TETS-Methyl benzoate 2107375-54-0 98%
    TETS-Methyl benzoate(compound 2j) is a haptendirectly conjugated to the carrier protein via carboxylic acid function using the standard activated ester method.
    TETS-Methyl benzoate
Cat. No. Product Name / Synonyms Application Reactivity